{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:27:25Z","timestamp":1772562445452,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1124\/dmd.124.001819","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:15:14Z","timestamp":1731086114000},"page":"1396-1406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy"],"prefix":"10.1016","volume":"52","author":[{"given":"Andrew K.L.","family":"Goey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Claire","family":"Mukashyaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilly","family":"East","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.124.001819_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1124\/dmd.124.001819_bib2","series-title":"(Casimersen) injection, for intravenous use. Prescribing information","year":"2023"},{"key":"10.1124\/dmd.124.001819_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/00498259409043235","article-title":"7-Ethoxycoumarin O-deethylase kinetics in isolated rat, dog and human hepatocyte suspensions","volume":"24","author":"Bayliss","year":"1994","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.124.001819_bib4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"key":"10.1124\/dmd.124.001819_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu Rev Neurosci"},{"key":"10.1124\/dmd.124.001819_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/dmd.124.001819_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1124\/dmd.124.001819_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3233\/JND-160157","article-title":"Toxicological characterization of exon skipping phosphorodiamidate morpholino oligomers (PMOs) in non-human primates","volume":"3","author":"Carver","year":"2016","journal-title":"J Neuromuscul Dis"},{"key":"10.1124\/dmd.124.001819_bib9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1124\/dmd.124.001819_bib10","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"10.1124\/dmd.124.001819_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/dmd.124.001819_bib12","series-title":"(Delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion Prescribing information","year":"2024"},{"key":"10.1124\/dmd.124.001819_bib13","series-title":"(Eteplirsen) injection, for intravenous use. Prescribing information","year":"2022"},{"key":"10.1124\/dmd.124.001819_bib14","series-title":"Drug interactions Flockhart table","author":"Flockhart","year":"2024"},{"key":"10.1124\/dmd.124.001819_bib15","series-title":"Platform technology designation program for drug development guidance for industry","year":"2024"},{"key":"10.1124\/dmd.124.001819_bib16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1124\/dmd.124.001819_bib17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"10.1124\/dmd.124.001819_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mus.28075","article-title":"Survival among patients receiving eteplirsen for up to 8\u2009years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls","volume":"70","author":"Iff","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1124\/dmd.124.001819_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/dmd.118.081729","article-title":"An assessment of the in vitro inhibition of cytochrome P450 enzymes, UDP-glucuronosyltransferases, and transporters by phosphodiester- or phosphorothioate-linked oligonucleotides","volume":"46","author":"Kazmi","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001819_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.124.001819_bib21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/dmcn.13934","article-title":"Duchenne muscular dystrophy and caregiver burden: a systematic review","volume":"60","author":"Landfeldt","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1124\/dmd.124.001819_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1124\/dmd.124.001819_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Eteplirsen Study Group and Telethon Foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1124\/dmd.124.001819_bib24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/JND-200548","article-title":"Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls","volume":"8","author":"Mendell","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1124\/dmd.124.001819_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.nmd.2023.03.008","article-title":"Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6\u201348 months with Duchenne muscular dystrophy amenable to exon 51 skipping","volume":"33","author":"Mercuri","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1124\/dmd.124.001819_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.nrl.2018.01.001","article-title":"Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy","volume":"34","author":"Nascimento Osorio","year":"2019","journal-title":"Neurologia (Engl Ed)"},{"key":"10.1124\/dmd.124.001819_bib27","unstructured":"Patel Y, Mukashyaka C, Yocum N, Elkins J, Rodino-Klapac LR, East L. (2023) Eteplirsen, golodirsen, and casimersen show consistent clinical pharmacology properties for the treatment of Duchenne muscular dystrophy. Presented at American Society for Clinical Pharmacology & Therapeutics 2023 Annual Meeting, March 22-24, 2023, Atlanta, GA."},{"key":"10.1124\/dmd.124.001819_bib28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mt.2008.287","article-title":"Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene","volume":"17","author":"Popplewell","year":"2009","journal-title":"Mol Ther"},{"key":"10.1124\/dmd.124.001819_bib29","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1002\/j.1460-2075.1988.tb03165.x","article-title":"Localization of the mdx mutation within the mouse dystrophin gene","volume":"7","author":"Ryder-Cook","year":"1988","journal-title":"EMBO J"},{"key":"10.1124\/dmd.124.001819_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1091581809359206","article-title":"Safety pharmacology and genotoxicity evaluation of AVI-4658","volume":"29","author":"Sazani","year":"2010","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.124.001819_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1091581811403504","article-title":"Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Sazani","year":"2011","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.124.001819_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1091581811403505","article-title":"Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of Duchenne muscular dystrophy","volume":"30","author":"Sazani","year":"2011","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.124.001819_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.124.001819_bib34","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: a point mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"10.1124\/dmd.124.001819_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug metabolism and pharmacokinetics of antisense oligonucleotide therapeutics: typical profiles, evaluation approaches, and points to consider compared with small molecule drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.124.001819_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.1985.tb02645.x","article-title":"Drug metabolising activity of freshly isolated human hepatocytes","volume":"19","author":"Tee","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.124.001819_bib37","series-title":"(Viltolarsen) injection, for intravenous use. Prescribing information","year":"2021"},{"key":"10.1124\/dmd.124.001819_bib38","series-title":"(Golodirsen) injection, for intravenous use. Prescribing information","year":"2021"},{"key":"10.1124\/dmd.124.001819_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.124.001819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T01:16:30Z","timestamp":1743642990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624159430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0090955624159430"],"URL":"https:\/\/doi.org\/10.1124\/dmd.124.001819","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Nonclinical Drug Metabolism and Pharmacokinetic Properties of Phosphorodiamidate Morpholino Oligonucleotides, a Novel Drug Class for Duchenne Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.124.001819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}